2-Methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine; compound with GENERIC INORGANIC NEUTRAL COMPONENT | 485402-39-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并吡啶类
• 英文名称: 2-Methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine; compound with GENERIC INORGANIC NEUTRAL COMPONENT
• 英文别名: 2-Methyl-4,5,6,7-tetrahydro-3H-imidazo[4,5-c]pyridine hydrochloride；2-methyl-4,5,6,7-tetrahydro-3H-imidazo[4,5-c]pyridine;hydrochloride
• CAS: 485402-39-9
• 化学式: C₇H₁₁N₃*2ClH
• 分子量: 210.106
• InChiKey: HUEZPVTYDITOPK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.79
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  40.7
• 氢给体数：
  3
• 氢受体数：
  2

安全信息

• 海关编码：
  2933990090

反应信息

• 作为产物：
  描述：

  2-甲基咪唑[4,5-C]吡啶 在 盐酸 、 水 、 三乙胺 作用下， 反应 10.0h， 生成 2-Methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine; compound with GENERIC INORGANIC NEUTRAL COMPONENT
  参考文献：
  名称：

  摘要：

  Reduction of-substituted [1,2,3]triazolo[4,5-c]pyridines with nickel-aluminum alloy in aqueous alkali gave 2-azaspinaceamines. Reduction of imidazo[4,5-c]pyridine and [1,2,3]triazolo[4,5-c]pyridine derivatives with formic acid in the presence of triethylamine resulted in formation of 5-formylspinaceamines and 2-azaspinaceamines. The 5-formyl group in the latter can be removed by acid hydrolysis. Unsubstituted 2-azaspinaceamine, an aza analog of natural spinaceamine, was synthesized for the first time.

  DOI：

  10.1023/a:1016350629395

文献信息

• NOVEL COMPOUNDS
  申请人：Gottschling Dirk

  公开号：US20110195954A1

  公开（公告）日：2011-08-11

  The present invention relates to new CGRP-antagonists of general formula I wherein U, V, X, Y, R 1 , R 2 , R 3 and R 4 are defined as mentioned in the description, the tautomers thereof, the isomers thereof, the diastereomers thereof, the enantiomers thereof, the hydrates thereof, the mixtures thereof and the salts thereof as well as the hydrates of the salts, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, medicaments containing these compounds, the use thereof and processes for the preparation thereof.

  本发明涉及一般式I的新CGRP拮抗剂，其中U、V、X、Y、R1、R2、R3和R4如描述中所述定义，其互变异构体、异构体、顺反异构体、对映异构体、水合物、混合物及其盐，以及其盐的水合物，特别是与无机或有机酸或碱形成的生理上可接受的盐，包含这些化合物的药物、其用途以及其制备方法。
• US8829006B2
  申请人：——

  公开号：US8829006B2

  公开（公告）日：2014-09-09